FDA rejects Mylan’s generic Advair again

Jun 15, 2018

Mylan announced that the FDA will not approve its Abbreviated New Drug Application for the generic version of GlaxoSmithKline's asthma drug, Advair Diskus, due to “minor deficiencies” in the application.

The deficiencies will be relayed in a Complete Response Letter on June 27, 2018. This is the second CRL Mylan has received from the FDA regarding its ANDA for a generic version of GSK’s best-selling asthma treatment — the first one was announced in March of last year.

According to Mylan, however, the damage isn’t that bad: because its ANDA has received a priority designation, approval could be received prior to the standard 90-day time period following the drugmaker's response to the Complete Response Letter.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments